FDA Expands Afrezza to Pediatric Diabetes - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

  • By

  • Kathryn Wighton

  • May 29, 2026

  • 3 min

Share

  • 1

    The FDA has approved Afrezza for children aged 6 and older with type 1 or type 2 diabetes.

  • 2

    Afrezza is an inhaled mealtime insulin that is administered using a portable inhaler.

  • 3

    The approval was supported by data from the INHALE-1 trial and over 20 years of inhaled insulin studies.

  • 4

    Afrezza offers a needle-free option for mealtime insulin, addressing challenges faced by pediatric patients.

  • 5

    Afrezza is not suitable for patients with chronic lung diseases and requires lung function assessments.

Original Source(s)

FDA Expands Afrezza to Pediatric Diabetes

  • by Kathryn Wighton

  • May 29, 2026

Related Content

FDA Grants Traditional Approval to Iptacopan in Primary IgAN

Novartis reported less annual eGFR decline with iptacopan than placebo over 2 years in the phase 3 APPLAUSE-IgAN trial.

Area-Based Marginalization and Incidence of Childhood Cancer

Does Pediatric Readiness Reduce ED Imaging?

Hospitals with stronger pediatric emergency capability used less imaging overall, but differences by insurance status and race and ethnicity remained.